An Open-Label, Dose-Escalation, Safety Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors

  • STATUS
    Not Recruiting
  • sponsor
    Incyte Europe Sàrl
Updated on 21 April 2022
solid tumors
solid tumor
advanced solid tumor

Summary

An Open-Label, Dose-Escalation, Safety Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors

Description

This purpose of this study is to explore the safety of INCAGN01876 in subjects with advanced or metastatic solid tumors. The study has 2 parts: Part 1 will determine the recommended dose of INCAGN01876, while Part 2 will further evaluate the recommended dose in subjects with certain tumor types (endometrial cancer, melanoma, non-small cell lung cancer, and renal cell carcinoma).

For more information, please contact Incyte Corporation (responsible party for Incyte Europe Sàrl) at +1 (855) 463-3463.

Details
Condition All Solid Tumors, Solid Tumors
Clinical Study IdentifierTX149864
SponsorIncyte Europe Sàrl
Last Modified on21 April 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note